Market Place
Sourcing Support
Septerna Appoints Gil Labrucherie As Chief Financial Officer
06 Jan 2025 //
GLOBENEWSWIRE
Septerna to Present at 43rd J.P. Morgan Healthcare Conference
18 Dec 2024 //
GLOBENEWSWIRE
Septerna Reports Q3 2024 Financial Results And Business Highlights
20 Nov 2024 //
GLOBENEWSWIRE
Septerna Announces Closing of $331.2 Million Upsized IPO
30 Oct 2024 //
GLOBENEWSWIRE
Septerna goes public with upsized offering of $288M
26 Oct 2024 //
FIERCE BIOTECH
Goldman-backed drug developer Septerna raises $288 mln in US IPO
24 Oct 2024 //
REUTERS
Septerna Prices Upsized Initial Public Offering
24 Oct 2024 //
GLOBENEWSWIRE
Septerna plans $158M IPO to fund readouts for GPCR pipeline
21 Oct 2024 //
FIERCE BIOTECH
GPCR firm Septerna files for IPO on strength of preclinical data
03 Oct 2024 //
FIERCE BIOTECH
Septerna Presents New Preclinical Data For PTH1R Agonists
30 Sep 2024 //
BUSINESSWIRE
Septerna Announces Phase 1 Trial With SEP-786 For Treatment
27 Sep 2024 //
BUSINESSWIRE
Septerna Appoints Veterans In Drug Development Roles
25 Sep 2024 //
BUSINESSWIRE
Septerna`s GPCR Platform Therapeutic Potential At ENDO 2024
03 Jun 2024 //
BUSINESSWIRE
Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 24
20 May 2024 //
BUSINESSWIRE
Septerna Appoints Bernard Coulie and Shalini Sharp to its Board of Directors
06 Feb 2024 //
BUSINESSWIRE
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
12 Sep 2023 //
BUSINESSWIRE
Vertex gets in on GPCR game, paying Septerna $47M for program
12 Sep 2023 //
FIERCE BIOTECH
Septerna Bolsters Leadership Team as Company Advances its Multi-Product Pipeline
31 Aug 2023 //
BUSINESSWIRE
Septerna snags $150M series B for next-gen GPCR drugs
11 Jul 2023 //
FIERCE BIOTECH
Septerna Secures $150 Million in Series B Financing
11 Jul 2023 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.